

## AGC Inc.

IR Day 2024 <Day 2> Life Science

June 4, 2024

# **Event Summary**

[Company Name]	AGC Inc.	
[Company ID]	5201-QCODE	
[Event Language]	JPN	
[Event Type]	Analyst Meeting	
[Event Name]	IR Day 2024 <day 2=""></day>	
[Date]	June 4, 2024	
[Venue]	Webcast	
[Number of Speakers]	2 Tadashi Murano Chikako Ogawa	Senior Executive Officer, President of Life Science Company General Manager of Corporate
		Communications & Investor Relations Division

### Presentation


**Ogawa**: The time has arrived, and Mr. Murano, President of Life Science Company, will give a presentation on the business strategy of the life science business. Mr. Murano, please go ahead.

Contents		Your Dreams, Our	FC
AC	iC		
1. Overview of Life Science Bu	isiness — P.3		
2. Current Situation and Futur	e Outlook P.7		
<b>3</b> . Business Strategy and Perfo	prmance Targets — P.9		
<b>4</b> . Appendix	P.16		
		©AGC Inc.	2

Murano: I am Murano of the life science company. Thank you.

I will now give a brief overview of our life science business.

# **Business Overview**




The AGC group's life science business is as you can see here.

Sales are on the left. To the right are the two main businesses of the life science business. One is the small molecule pharmaceuticals and agrochemicals CDMO, and the other is biopharmaceuticals CDMO. The details of the service are as described here.

# **Financial Performance**

 In 2023, sales and profits declined due to the delay in the launch of new US lines and the deterioration in the market environment, but the scale of the business increased steadily thanks to intensive investment.



Next page, please. This is the performance trend of the life science company segment.

The graph from 2018 shows that we have achieved a growth rate of over 30% per year until 2022. However, if you look at 2023, the reality is that the brakes have been applied.

The contents are described here. Both sales and performance have temporarily deteriorated in 2023. The main reasons for this are the deterioration of the biopharmaceuticals CDMO market environment, the delay in the launch of a new line of biopharmaceuticals CDMO in the US, and the cost of large, aggressive investments that we had already prepared for.

As for the sales breakdown of the life science company, as shown in the graph on the right, 70% are biopharmaceuticals CDMO and 30% are small molecule pharmaceuticals and agrochemicals CDMO.

# **History of Life Science Business**

 In 1973, the Life Science Team was launched as a research unit, and commercial operations began in the 80s.

# 1973 Launched The Life Science Team to investigate the applicability of AGC's fluorination technology to pharmaceutical & agrochemical production

Small molecule pharmaceuticals/agrochemicals	Biopharmaceuticals	
1985 Started contract manufacture/supply of fluorinated intermediates for use in antibiotics	1984 Formed the Biochemical Group focused on biopharmaceutical development	
1997 Established AGC Wakasa Fine Chemicals (currently AGC Wakasa Chemicals)	2000 Formally launched the protein contract manufacturing business	
2003 Established a GMP-compliant manufacturing facility for clinical stage drug	2008 Established a new facility at Chiba Plant with 10-fold higher capacity	
substances & intermediates at Chiba Plant	2016 Acquired biopharmaceuticals CDMO in German (currently Heidelberg site)	
2008 Obtained marketing approval for tafluprost, an anti-glaucoma drug substance	2017 Acquired biopharmaceuticals CDMO with sites in Europe and US (currently Seattle & Copenhagen sites)     2020 Established new mammalian cell culture facility at Chiba Plant	
2013 Established a new plant, Kaminaka Plant, in the Wakasa Techno-Valley (AGC Wakasa Chemicals)		
2019 Acquired drug substance manufacturing plant in Spain (currently AGC Pharma		
Chemicals Europe)	2020 Acquired biopharmaceutical drug substance manufacturing plant in US (currently Boulder site)	
2019 Increased GMP compliant production capacity 10-fold at Chiba Plant		
2020 Decided to expand facilities at AGC Pharma Chemicals Europe	2020 Acquired gene/cell therapy CDMO in Italia (currently Milan site)	
2021 Decided to expand facilities at Kaminaka Plant of AGC Wakasa Chemicals	2021 Acquired U.S. gene therapy manufacturing plant (currently Longmont site)	
2022 Decided to expand facilities at AGC Pharma Chemicals Europe	2023 Started mRNA CDMO service (Heidelberg site)	

©AGC Inc. 6

Next page, please. Here is the history of the AGC group's life science business.

As you can see in the various details, in 1973, the life science team was launched, and commercial operations began in the '80s. In particular, with regard to biopharmaceuticals, our history is that in 2000, we formally launched the protein contract manufacturing business at our Chiba Plant, and since 2016, we have been expanding our biopharmaceuticals CDMO business, mainly through M&A.

### AGC

#### **Current Situation and Outlook of Biopharmaceuticals CDMO**

- The impact of the reduced capital inflows into biotech ventures continues. Although the business environment is recovering, its recovery pace requires close monitoring. The situation going forward will be assessed and necessary measures will be taken.
- New lines in the U.S. has resumed commercial operations and is expected to contribute to improvement in earnings from 2024.

AC

Current Situation* Continue to be affected by reduced capital inflows into biotech ventures, but recovery signs are seen. Implemented a rationalization to improve business performance Drastic measures implemented and resumed commercial operations in end of 2023   Business environment is recovering, but the recovery pace will be closely Slowly contributes to		Business environment	Launch of new lines in the U.S.
Current ituation* Continue to be affected by reduced capital inflows into blotech Ventures, but recovery signs are seen. implemented and resumed commercial operations in end of 2023   Business environment is recovering, but the recovery pace will be closely monitored to consider and take additional measures according to Slowly contributes to improvement in earnings	Issues		Delay in launching new lines at Boulder site in the U.S.
Dutlook monitored to consider and take additional measures according to improvement in earnings		but recovery signs are seen.	implemented and resumed commercial operations in
	outlook	monitored to consider and take additional measures according to	improvement in earnings

Let me explain the current situation on page eight. I touched on this a little earlier, but I would like to explain the status of biopharmaceuticals CDMO in particular.

The impact of the decrease in capital inflows with respect to the main customers of the AGC group biopharmaceuticals CDMO, which is called biotech ventures, had started in 2023, and we now see that it is still continuing to some extent. The business environment itself is recovering on the actual front, but we are not very optimistic about the pace of recovery.


We believe that in the medium to long term, there will be a definite recovery, including the supply-demand balance, but we think that we need to be more cautious about the pace of recovery this year. We will take various measures according to the situation.

The new biopharmaceuticals CDMO line in the US, which had a large impact on our business performance last year, is located at our plant in Colorado, and last year, it was barely in operation, which had a considerable impact on our business performance. This line has resumed commercial operation this year, and we expect it to contribute to improved business performance this year and next.

Those things are written here, and as I have just told you about the launch of the new line, we expect it to make a significant contribution to our business performance from now on into next year.

### **Business Environment Outlook**

AGC



• With the trend towards increased outsourcing, the CDMO market is expanding steadily.

I will now explain our business performance and business strategy starting from the next page.

First, the business environment. Page 10 is the market for drug substance CDMO, which is our industry. This is the assumption of the market size.

Although there was a temporary problem with the capital inflows from biotech ventures, etc. in 2023, we are almost certain that the CDMO business will grow in the mid- to long-term as the pharmaceutical industry moves to outsource production to CDMO companies like AGC.

The CAGR is shown on the right side of the chart and looking at the investment by CDMO companies and the expansion of supply capacity, we expect that the demand-supply balance will remain quite strong at least until 2030. In particular, the small molecule pharmaceuticals at the bottom are expected to show stable growth, while the purple and orange biopharmaceuticals products above are expected to grow significantly.

#### Vision and AGC's Strengths AC Vision Strengths **1.** Providing a high standard of services To contribute to bettering the integrated from 10 sites in three world, by providing high-quality regions of Japan, the US, and Europe life-science related services & 2. Flexible production system providing services from early-stage products, that require high-level development to commercial phase expertise & competence 3. Extensive Manufacturing and Inspection Track Record ©AGC Inc. 11


The next page shows AGC's strengths.

Our strengths include the ability to provide a high standard of CDMO services at 10 sites in three regions, Japan, the US, and Europe, and to handle everything from early-stage development to commercial phase. We believe that each of our global sites has strengths as a trusted CDMO because of their extensive manufacturing experience and track record of inspections called FDA and EMA.

The AGC group is a materials manufacturer, and in the mid- to long-term, we believe that we can differentiate ourselves from our competitors by applying technologies that are unique to the AGC group, such as digital or materials informatics.

# Strengths | Flexible to production needs from early-stage development to commercial scale

 Addresses a wide range of production scale needs that vary in accordance with the progress of the development phase of the drug product



\* AGC estimates


©AGC Inc. 12

The page 12 shows what I have just discussed.

One of our characteristics is that we are engaged in both small molecule pharmaceuticals and biopharmaceuticals, and we have a flexible production system from early-stage development to commercial scale.

# Strategies and measures





\*Bioreactors using disposable containers called single-use bags


©AGC Inc.

Next page, please. This is a short- and medium-term strategy.

Basically, we are planning to further expand small molecule pharmaceuticals, agrochemicals, and biopharmaceuticals business, as well as to expand our modality in terms of technology.

#### Business strategy based on the market maturity of each modality

AGC




The next page is specifically for modalities.

We are aggressively investing in our mature small molecule pharmaceuticals and proteins, as well as in growing antibody drugs, future gene/cell therapy, and mRNA, and we intend to adopt business strategies accordingly.

# Life Science Segment Performance Targets

- We aim to achieve operating profit of over 30 billion yen and ROCE of over 10% by 2026.
- Continue to consider and take measures to improve business performance based on the current extremely severe business environment.



Finally, our medium- to long-term performance targets.

As I mentioned earlier, in 2023, sales were temporarily affected by the market environment and capital investment was made here, resulting in a one-time drop in operating profit, but we believe that the market will recover in the mid- to long term and we will grow in this manner.

By 2026, we intend to achieve performance targets on the scale described here. That is all the explanation from me.

**Ogawa**: Thank you very much, Mr. Murano.

[END]